Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE

<< Previous

Bullboard Posts

Next >>

Post by Pronorvistaon Nov 06, 2023 10:55am

282 Views

Post# 35719367

ATE

Last chance before the big departure.

Market By Order

Price	Volume	House	Time
0.860	2,000	TD Sec	09:40
0.850	1,000	ITG	09:44
0.850	5,000	TD Sec	09:26
0.850	25,000	Anonymous	Oct 25
0.840	1,000	Leede	Oct 20
0.830	1,000	Raymond James	10:01
0.830	1,000	Scotia	Nov 3
0.830	4,500	TD Sec	Oct 20
0.820	500	Canaccord	10:27
0.820	6,500	Mackie	09:44
0.810	4,000	TD Sec	10:27
0.810	500	CIBC	10:51
0.810	42,000	Raymond James	10:51
0.800	1,000	Ind Trading	Nov 3
0.800	500	Canaccord	10:13
0.790	500	CIBC	10:15
0.780	500	Anonymous	Nov 3
0.780	5,000	Ind Trading	Nov 3
0.780	800	Desjardins	09:13
0.770	500	Ind Trading	Nov 3